Get the Stockscreener App
473.13
0.66%
3.23
Vertex Pharmaceuticals Inc stock is traded at $473.13, with a volume of 396.30K.
It is up +0.66% in the last 24 hours and up +4.62% over the past month.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
See More
Previous Close:
$469.90
Open:
$466.79
24h Volume:
396.30K
Relative Volume:
0.28
Market Cap:
$120.01B
Revenue:
$11.74B
Net Income/Loss:
$3.68B
P/E Ratio:
33.35
EPS:
14.1888
Net Cash Flow:
$3.34B
1W Performance:
-0.80%
1M Performance:
+4.62%
6M Performance:
+2.36%
1Y Performance:
+2.46%
1-Day Range:
$464.01
$473.74
1-Week Range:
$464.01
$485.00
52-Week Range:
$362.50
$519.68
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Name
Vertex Pharmaceuticals Inc
Sector
Industry
Phone
(617) 341-6393
Address
50 NORTHERN AVENUE, BOSTON, MA
Compare VRTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
473.00 | 119.22B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.29 | 77.93B | 14.34B | 4.50B | 3.88B | 41.57 |
|
ARGX
Argen X Se Adr
|
839.30 | 52.01B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
338.66 | 44.66B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
342.30 | 37.67B | 4.98B | 69.60M | 525.67M | 0.5198 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Resumed | Barclays | Overweight |
| Jan-22-26 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jan-12-26 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jan-07-26 | Resumed | UBS | Buy |
| Jan-06-26 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-03-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Sep-25-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Sep-03-25 | Initiated | Raymond James | Mkt Perform |
| Aug-06-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| May-07-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| May-06-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-12-25 | Upgrade | Canaccord Genuity | Sell → Hold |
| Feb-11-25 | Upgrade | Canaccord Genuity | Sell → Hold |
| Jan-30-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-20-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-09-24 | Upgrade | Jefferies | Hold → Buy |
| Nov-14-24 | Initiated | Citigroup | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Perform |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Aug-05-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-27-24 | Initiated | Redburn Atlantic | Buy |
| Apr-11-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Feb-06-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-02-24 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-31-24 | Downgrade | Maxim Group | Buy → Hold |
| Jan-31-24 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-24-24 | Downgrade | Canaccord Genuity | Hold → Sell |
| Dec-14-23 | Reiterated | RBC Capital Mkts | Sector Perform |
| May-30-23 | Initiated | William Blair | Outperform |
| May-04-23 | Resumed | Piper Sandler | Overweight |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Jan-18-23 | Initiated | Canaccord Genuity | Hold |
| Jan-17-23 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Dec-19-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-01-22 | Upgrade | Maxim Group | Hold → Buy |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| May-06-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-03-22 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-03-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-27-22 | Reiterated | JP Morgan | Overweight |
| Jan-27-22 | Reiterated | Morgan Stanley | Underweight |
| Jan-27-22 | Reiterated | RBC Capital Mkts | Outperform |
| Jan-27-22 | Reiterated | Stifel | Hold |
| Jan-27-22 | Reiterated | Wolfe Research | Outperform |
| Jan-20-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Nov-19-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-09-21 | Downgrade | Stifel | Buy → Hold |
| Sep-07-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-20-21 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-19-21 | Resumed | Wolfe Research | Outperform |
| Jul-01-21 | Initiated | Raymond James | Mkt Perform |
| Jun-11-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Feb-23-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Feb-02-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-30-20 | Initiated | Daiwa Securities | Outperform |
| Nov-30-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-20-20 | Initiated | Bernstein | Outperform |
| Oct-28-20 | Initiated | UBS | Buy |
| Jul-31-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-30-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-28-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-31-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-19-19 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Sep-03-19 | Upgrade | Goldman | Neutral → Buy |
| Aug-01-19 | Downgrade | Needham | Buy → Hold |
| May-23-19 | Resumed | Citigroup | Buy |
| May-21-19 | Initiated | Credit Suisse | Outperform |
| Apr-12-19 | Initiated | Evercore ISI | In-line |
| Mar-26-19 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-19-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-06-19 | Downgrade | Maxim Group | Buy → Hold |
View All
Vertex Pharmaceuticals Inc Stock (VRTX) Latest News
Principal Financial Group Inc. Reduces Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Atle Fund Management AB Reduces Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Holdings Lifted by National Pension Service - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by TD Waterhouse Canada Inc. - MarketBeat
Vertex Pain Setback Prompts Fund Exit And Recheck Of Valuation Gap - Yahoo Finance
Why Analysts Are Positive on Vertex Pharmaceuticals Incorporated (VRTX)'s Story - Finviz
Biotech Stocks To Keep An Eye OnJanuary 31st - MarketBeat
Why Analysts Are Positive on Vertex Pharmaceuticals Incorporated (VRTX)’s Story - Insider Monkey
Welch & Forbes LLC Buys 3,102 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
AustralianSuper Pty Ltd Trims Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Why Vertex Pharmaceuticals (VRTX) Dipped More Than Broader Market Today - Yahoo Finance
Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Fidelis Capital Partners LLC - MarketBeat
Prediction: 2026 Will Be the Year of Vertex Pharmaceuticals - The Globe and Mail
Best Biotech Stocks To Watch NowJanuary 29th - MarketBeat
What's Driving the Market Sentiment Around Vertex Pharmaceuticals Inc? - Benzinga
Assessing Vertex Pharmaceuticals (VRTX) Valuation After Fund Exit And Setback For Journavx Pain Label - simplywall.st
Vertex Pharmaceuticals Incorporated $VRTX Shares Acquired by Strategic Advisors LLC - MarketBeat
Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) Presents a Compelling Value Case - Chartmill
New York State Common Retirement Fund Cuts Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Mirae Asset Global Investments Co. Ltd. Buys 6,468 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Truist Financial Corp Sells 66,225 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharma upgraded at RBC Capital Markets citing upside in 2026 - MSN
Barclays Upgrades Vertex Pharmaceuticals (VRTX) - Nasdaq
Promising Biotech Stocks To ResearchJanuary 28th - MarketBeat
Barclays Upgrades Vertex Pharmaceuticals (VRTX) with Increased P - GuruFocus
Bank of America Securities Keeps Their Buy Rating on Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Little House Capital LLC Increases Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Stonegate Investment Group LLC Has $769,000 Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Here’s Why Hardman Johnston Global Equity Strategy Sold Vertex Pharmaceuticals (VRTX) - Yahoo Finance
Vertex Pharmaceuticals (VRTX) Receives a Buy from Citi - The Globe and Mail
Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by EFG Asset Management North America Corp. - MarketBeat
Autologous Cell Therapy Market Size to Reach US$ 44.55 Billion by 2033 | Astute Analytica - GlobeNewswire Inc.
Promising Biotech Stocks To Follow NowJanuary 27th - MarketBeat
Barlow Wealth Partners Inc. Sells 21,078 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Physician Views Results: Vertex's Journavx impresses in acute pain, as case for chronic comes into focus - FirstWord Pharma
VRTX Stock Surges 6.1% With A 5-day Winning Spree On Analyst Upgrades - Trefis
TIME100 Most Influential Companies 2025: Vertex Pharmaceuticals - Time Magazine
Vertex Pharmaceuticals (VRTX) Stock Analysis: A Biotech Leader With 8% Potential Upside - DirectorsTalk Interviews
Vertex Pharmaceuticals (VRTX) Sees Price Target Increase by UBS to $545 | VRTX Stock News - GuruFocus
Best Biotech Stocks To Follow NowJanuary 26th - MarketBeat
Vertex Pharmaceuticals price target raised to $545 from $535 at UBS - TipRanks
Lbp Am Sa Grows Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
UniSuper Management Pty Ltd Has $8.03 Million Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Baillie Gifford & Co. Sells 5,423 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
AMF Tjanstepension AB Reduces Stock Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
A Look At Vertex Pharmaceuticals (VRTX) Valuation After Recent Analyst Upgrades And CASGEVY Approval - Yahoo Finance
Y Intercept Hong Kong Ltd Takes $10.88 Million Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
How Evolving Analyst Assumptions Are Reshaping The Story For Vertex Pharmaceuticals (VRTX) - Yahoo Finance
Resona Asset Management Co. Ltd. Sells 4,351 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Jennison Associates LLC Decreases Stock Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Strs Ohio Has $31.58 Million Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Inc Stock (VRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Vertex Pharmaceuticals Inc Stock (VRTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| WAGNER CHARLES F JR | EVP, CO & FO |
Jan 06 '26 |
Option Exercise |
189.38 |
9,532 |
1,805,170 |
47,257 |
| WAGNER CHARLES F JR | EVP, CO & FO |
Jan 06 '26 |
Sale |
461.00 |
9,532 |
4,394,252 |
37,725 |
1.74%
1.92%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):